Biyun Tian has a core technology platform with independent intellectual property rights, and has established a complete product line covering basic scientific research to drug development, including more than 2000 products such as ELISA kits, antibodies, and apoptosis detection reagents. The company strictly adheres to international quality standards and has obtained ISO 9001 and ISO 13485 certifications. Its products are exported to over 60 countries and regions worldwide. Biyun Tian attaches great importance to industry university research cooperation, maintains long-term strategic partnerships with top institutions such as the Chinese Academy of Sciences and Fudan University, and continues to promote the innovative development of life science research in China.

In recent years, Biyun Tian has maintained an average annual business growth rate of over 20%, with sales exceeding 1 billion yuan in 2023. The company is expanding its intelligent production base and accelerating its layout in cutting-edge technology fields such as organoid culture and single-cell sequencing. In the next three years, Biyun Tian plans to increase its overseas market expansion efforts, focusing on developing diagnostic grade reagents that meet international standards, and is committed to becoming a globally influential life science brand.